SUBSCRIBE
SUBSCRIBE
News   Drug Development

AVANIR Pharmaceuticals Announces Last Patient Enrolled In Neuropathic Pain Phase III Trial With Zenvia

November 15, 2006 | 
1 min read
SAN DIEGO--(BUSINESS WIRE)--AVANIR Pharmaceuticals (NASDAQ:AVNR) announced today that the Company has enrolled the targeted number of patients needed to assess the efficacy endpoint in its ongoing Zenvia Phase III painful diabetic neuropathy trial.
Clinical research Phase III
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ECLIPSEBIO
The mRNA Revolution You Haven’t Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
July 10, 2025
 · 
1 min read
 · 
Lori Ellis
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Business consultant. Hands help a businessman is falling from a graph vector
Rare diseases
Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short
July 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Dementia and mental health recovery treatment and Alzheimer brain memory disease therapy concept as old trees recovering as a neurology or psychology and psychiatry cure metaphor with 3D illustration elements on a white background.
Startups
Longevity Biotechs Strive for Better Aging—Not Just Life Extension
July 9, 2025
 · 
3 min read
 · 
Tristan Manalac